Gold-specific T lymphocyte clones were isolated from a patient with rheumatoid arthritis who developed delayed type hypersensitivity reactions to gold. All of the isolated T cell clones required histocompatible antigen presenting cells as well as gold for induction of proliferation. Using a panel of HLA-homozygous Epstein Barr virus-transformed B (EBV-B) cells and anti-HLA antibodies, the clones were shown to recognize gold in the context of DR1 molecules. Gold recognition did not require active antigen processing since specific proliferation was not affected by glutaraldehyde fixation of the DR1 homozygous antigen presenting cells. Furthermore, we could show that gold salts inhibited peptide-induced responses of a peptide-specific T cell clone. In addition to providing evidence for goldspecific T cells in gold-treated RA patients exhibiting delayed type hypersensitivity responses, these data suggest that gold can alter MHC-peptide complexes. The latter observation may in part explain the mechanism/s responsible for both the therapeutic and the toxic effects of gold.
Introduction
Rheumatoid arthritis is a common autoimmune disease which is characterized by chronic inflammation of the joints. The presence of lymphocytic infiltrates (1, 2) and the association of the disease with specific MHC class II determinants (reviewed in 3), which control antigen presentation to T cells, suggest that autoreactive T lymphocytes may initiate and/or -maintain the inflammatory process.
Compounds containing gold in the Au(I) state, such as gold sodium thiomalate and gold thioglucose, are among a small number of agents which are able to arrest the progression of RA3 and which can even induce remissions in some patients (4) (5) (6) (7) . However, in up to one-third of the patients treatment has to be stopped because of toxicity (8) . The most common Dr. Romagnoli's present address is National Institutes ofHealth, Building 10 Receivedfor publication 6 March 1991 and in revisedform 29 July 1991. toxic effects are delayed type hypersensitivity reactions involving the skin and the mucous membranes (9) . Neither the mechanism/s responsible for the therapeutic nor the toxic effects of gold salts have been elucidated (10) .
Here we describe the effect of gold on antigen presentation by studying recognition ofgold compounds by T cells from RA patients who had developed hypersensitivity reactions to gold, and by examining the effect of gold on peptide presentation to T cells.
Methods
Patients. Two patients (1 male and 1 female) with RA (A.M. and V.W.) who received gold sodium thiomalate (AuTM), participated in this study after giving informed consent. The patients were 56 and 63 years old and the diagnosis of RA had been made 5 and 12 months earlier according to the 1958 American Rheumatism Association criteria for definite and classical RA.
Patient A.M. received AuTM at an initial dose of 20 mg weekly for the first two weeks followed by 50 mg/wk. After four weeks of therapy the patient developed a pruritic eczematous dermatitis involving the trunk and the extremities. Chrysotherapy was discontinued, and the skin rash resolved completely within two months of onset.
Patient V.W. was also treated with AuTM with 20 mg/wk for the first two weeks and then with 50 mg/wk for a total of25 weeks. Thereafter the dosage interval was prolonged to 50 mg/mo. 11 months after initiation ofchrysotherapy and having received a cumulative gold dose of 1,440 mg the patient developed a pruritic irregular lichen planus-like rash. Gold therapy was discontinued.
HLA typing. HLA typing was performed by restriction fragment length polymorphism analysis on genomic DNA from EBV-B cells of patient A.M. The class II antigens detected were HLA DRI,1 and DQw5,w5.
Antigen. Gold thioglucose (AuTG) was obtained from Serva, Heidelberg, FRG, HAuCl4 from Aldrich Chemical Co., Steinheim, FRG, and Tauredon (gold content 46%) from Byk Gulden GmbH, Konstanz, FRG, was used as source AuTM.
The recombinant malaria fragment 190L used in the fixation experiment was described previously (1 1).
Culture media. The culture medium RPMI 1640 (Gibco, Paisley, Scotland) was supplemented with L-glutamine (2 mM), sodium pyruvate (1 mM), 5 x I0' M 2-mercaptoethanol, 1% of a IOOX mixture of nonessential aminoacids (Gibco), 50 U/ml penicillin, 50 U/ml streptomycin, and 10% heat-inactivated fetal calf serum (RPMI-FCS) or 10% pooled human AB serum (RPMI-HS). To support the antigen-independent growth of T cell clones, RPMI-HS was supplemented with 100 U/ml recombinant human IL2 (rIL2; Hoffmann-La Roche, Inc., Nutley, NJ).
Lymphocyte proliferation assay. 10 ml heparinized whole blood was taken from the two RA patients 1-2 wk after discontinuation of chrysotherapy and PBMC isolated by Ficoll-Hypaque, Pharmacia Fine Chemicals, Uppsala, Sweden. Cells were washed twice, adjusted to a concentration of 4 x 106 cells/ml in RPMI-HS and added to wells of 96-well flat-bottomed plates in 1 00-id vol. Gold compounds at increasing concentrations (ranging from 0.1 to 100 ug/ml) were added, in Isolation of T cell clones. T cell clones (TLC)' were generated as previously described (12, 13 Two of the clones (AM 1 and AM48) were subcloned at 0.1 cells/ well. The probability of clonality for each subclone was 98% as determined by Poisson analysis. The subcloning procedure was identical with that described above. The independent clonal origin ofTLC AM I and AM48 was ascertained by genomic Southern blot analysis (EcoRI, BamHII, HindIII) using a human T cell receptor fd chain constant region probe (Cfl2 region 0.3 AvaIl fragment). The clones were expanded and maintained in culture by periodic restimulation (2-6 wk) in the presence of allogeneic irradiated PBMC, 2 ,g/ml PHA-P and rIL2.
To test the specificity of the T cell clones in a proliferation assay, cloned T cells (2 x 104) were cocultured in triplicate with 1 X 104 antigen-presenting cells (APC) (irradiated [7,000 rad] autologous or DR-homozygous Epstein-Barr virus B cells) in 0.2 ml of RPMI-HS with the different gold compounds (10 Ag/ml) or without antigen.
[3H]thymidine incorporation was measured 72 h later.
TLC AH.L16, used as control in the fixation experiment, recognizes peptide 344-355 of the Plasmodiumfalciparum blood stage p190 protein and DR I molecules (14) .
The derivation and characterization of the T cell clone used in the competition assay have been described elsewhere (15) .
EBV HAuCI4 or medium alone, washed four times, and irradiated before T cells were added and proliferation assayed as above.
Glutaraldehyde fixation of EB V-B cells. B cells were fixed as described by Shimonkevitz et al. (19) . Briefly, EBV-B cells were sedimented, resuspended in Hanks' medium (Gibco, Paisley, Scotland), and fixed with 0.05% glutaraldehyde for 1.5 min. The reaction was stopped by adding RPMI-FCS. The cells were sedimented, washed twice, pulsed for 2 h at 370C with 20 gg/ml of different gold compounds or medium alone, and washed four times before T cells were added and proliferation assayed as described above.
Effect ofgold on peptide-and anti-CD3-induced activation. Competition for antigen presentation has been described elsewhere (20) . Briefly, autologous EBV-B cells were fixed by resuspending them in 0.025% glutaraldehyde for 90 s. 
Results
HAuCl4 and to a lesser extent AuTM and AuTG induced proliferation of PBMC from two RA patients (A.M. and V.W.) who developed hypersensitivity reactions to gold therapy (Table I) , but did not induce proliferation of PBMC from either a RA patient on gold therapy but with no gold-induced toxic reactions, or from seven normal individuals (data not shown). The HAuCl4-stimulated cells from donor A.M. were expanded in IL2-containing medium and cloned in the presence of phytohemagglutinin and allogeneic antigen presenting cells as described (12, 13 (Fig. 1) . All clones were CD4' and CD8-. trol DRl restricted TLC (AH.LI6), specific for a malaria p190 peptide ( 14) . or presence of different concentrations of HAuCl4. After pulsing, the APC were washed and used as stimulator cells for the corresponding T cell clones. The results of these experiments are shown in Fig. 3 . Gold blocked the T cell proliferative response of BH26 T cells. Essentially similar results were obtained with AuTG and AuTM. Inhibition did not result from nonspecific toxic effects, as 50% inhibition ofantigen presentation was attained with only 3 ,ug/ml of HAuCl4, a concentration lower than the gold dose required for optimal activation of gold-specific T cells. In addition anti-CD3-induced proliferation of BH26 TLC was not affected by HAuCl4. adequate explanation for the therapeutic effect and/or the toxic reactions has remained elusive. Since autoreactive T cells are thought to initiate and maintain chronic inflammatory synovitis in rheumatoid arthritis, it seems reasonable to suggest that the therapeutic effect ofgold compounds is based on their ability to modify immunological processes (21) . In recent years considerable progress has been made in understanding the recognition of antigens by T cells. The T cell receptors interact with complexes which are formed by antigen fragments and MHC class I or class II molecules (22) (23) (24) (25) (26) (27) . The recognition ofthis complex by T cells is required for the generation of an immune response. It is possible that gold suppresses immune responsiveness by altering MHC-peptide complexes. Therefore we have studied the recognition of gold compounds by T cells. Our study shows that lymphocytes of patients who developed toxic skin reactions to gold proliferate in vitro when challenged with different gold compounds.
Discussion
The T cell response to gold does not seem to be due to in vitro priming as suggested to occur in other systems (15, 28) . In fact no response to gold was obtained with PBMC of several healthy controls as well as with PBMC of a RA patient on gold therapy but with no gold-induced toxic reactions (data not shown).
Gold-specific T cell clones respond to gold (I) (AuTG and AuTM) as well as gold (III) (HAuCl4). Since the most common oxidation state of gold in the presence of proteins containing thiols is gold (I) (29), we propose that in our culture conditions gold-specific T cells recognize gold in the oxidation state of gold (I). This view is further supported by the finding that preincubation of gold (III) with a fivefold molar excess of the strong reducing agent glutathione did not affect the ability of the gold to stimulate gold-specific clones (data not shown). These findings are difficult to reconcile with studies by Schuhmann et al. suggesting that gold (III) but not gold (I) was responsible for the capacity to sensitize T cells in an animal model (30).
Gold could generate the stimulatory structure(s) for T cells either by modifying antigens before their association with the presenting class II molecules or by modification of preformed MHC-peptide complexes. To distinguish between these two possibilities we have examined the ability of EBV-B cells to . c present gold before and after their fixation. Interestingly, glutaraldehyde fixation had no effect on the ability of APC to present gold to T cell clones. Since the present observations suggest that gold can bind to and alter preformed MHC-peptide complexes, we investigated whether gold could inhibit the presentation of a known peptide to T cells. The malaria peptide-specific T cell clone tested was inhibited by gold, consistent with the idea that gold has the ability to alter the stimulatory complex that is recognized by T cells. This model is attractive as it could provide an explanation for both the therapeutic and the toxic effects of gold treatment. Modification of putative "autoimmune peptide-MHC complexes" by gold would prevent the stimulation of autoaggressive T cells and in turn elicit gold-specific T cells that could be responsible for the delayed-type hypersensitivity reactions observed in some patients. The inhibitory effect of gold, however, may be more complex than the interpretation given above. Although anti-CD3-induced activation was not affected by gold, we cannot as yet rule out the possibility that gold could interfere with other molecules distinct from MHC, but involved in T cell activation. Future experiments will be undertaken to establish the precise inhibitory mechanism ofgold on peptide presentation. N
